id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2012-D-0307-0071,FDA,FDA-2012-D-0307,Recommendations to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Components,Other,Guidance,2022-05-24T04:00:00Z,2022,5,2022-05-24T04:00:00Z,,2024-11-07T00:39:23Z,,1,0,09000064850df573
FDA-2012-D-0307-0070,FDA,FDA-2012-D-0307,Recommendations To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Components; Guidance for Industry; Availability,Notice,Notice of Availability,2022-05-24T04:00:00Z,2022,5,2022-05-24T04:00:00Z,2022-05-25T03:59:59Z,2022-05-25T01:01:14Z,2022-11119,0,0,09000064850dbd5c